Stroke/Cerebrovascular Disease
-
Dual Antiplatelet Therapy Reduces Stroke Recurrence Risk
Compared to using just one antiplatelet drug, dual antiplatelet therapy started soon after ischemic stroke reduced the risk of recurrence without increasing the risk of major bleeding.
Reuters Health Information, February 7, 2012
-
Vorapaxar Meets End Point But Ups Bleeding
In its second phase 3 trial, Merck's novel antiplatelet agent reduced ischemic events but increased bleeding, including ICH. Results looked more promising in patients without a history of stroke.
Heartwire, February 7, 2012
-
Bypass Surgery for Stroke Prevention
Medscape General Surgery, January 12, 2012
-
Afib, Severe Sepsis, and the Risk for Stroke and Death
Medscape Pulmonary Medicine, December 22, 2011
-
Sonothrombolysis for Intracerebral Hemorrhages
Medscape Neurology, December 9, 2011
-
Stenting or Medication for Intracranial Arterial Stenosis?
Medscape Neurology, December 1, 2011
-
Cardiac Complications in Acute Ischemic Stroke
Western Journal of Emergency Medicine, January 29, 2012
-
Higher CHADS2 Scores Predict Worse Outcomes
Journal Watch, January 26, 2012
-
Sodium Excretion and Elevated Cardiovascular Morbidity
Journal Watch, January 24, 2012
-
Peripheral Leukocyte Counts and Outcomes After ICH
Journal of Neuroinflammation, January 24, 2012
-
Management of Asymptomatic Carotid Artery Stenosis
Neurosurgical Focus, January 23, 2012